Alpha 2.0
Login Register
» Authors » Herman Goossens

Herman Goossens

Explore the profile of Herman Goossens including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 472
Citations 24812
Followers 0
Related Specialties
Infectious Diseases
Microbiology
General Medicine
Top 10 Co-Authors
Samuel Coenen
Surbhi Malhotra-Kumar
Christine Lammens
Margareta Ieven
Ann Versporten
Paul Little
Niel Hens
Christopher C Butler
Basil Britto Xavier
Niels Adriaenssens
Published In
J Antimicrob Chemother
Lancet Infect Dis
PLoS One
J Clin Microbiol
BMJ Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Kasbergen L, de Bruin E, Chandler F, Sigfrid L, Chan X, Hookham L, et al.
Lancet Infect Dis . 2025 Feb; PMID: 39987930
Background: Arboviruses are increasingly affecting Europe, partly due to the effects of climate change. This increase in range and impact emphasises the need to improve preparedness for emerging arboviral infections...
2.
Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Sigfrid L, Chan X, Kasbergen L, Hookham L, Wei J, Chen S, et al.
Lancet Infect Dis . 2025 Feb; PMID: 39987929
Background: Arboviruses have expanded into new regions in Europe, yet data indicate gaps in disease notifications and a risk of further spread. We aimed to report on prevalence, clinical management,...
3.
The effect of a general practitioner's perception of a patient request for antibiotics on antibiotic prescribing for respiratory tract infections: secondary analysis of a point prevalence audit survey in 18 European countries
Domen J, Aabenhus R, Balan A, Bongard E, Bohmer F, Bralic Lang V, et al.
BJGP Open . 2025 Jan; PMID: 39824603
Background: Illness severity, comorbidity, fever, age and symptom duration influence antibiotic prescribing for respiratory tract infections (RTI). Non-medical determinants, such as patient expectations, also impact prescribing. Aim: To quantify the...
4.
Tracing carriage, acquisition, and transmission of ESBL-producing Escherichia coli over two years in a tertiary care hospital
Nguyen M, Gladstone B, De Angelis G, Biggel M, Xavier B, Lammens C, et al.
Genome Med . 2024 Dec; 16(1):151. PMID: 39707490
Background: The impact of community carriage on the influx of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) into hospitals remains understudied. In this prospective 2-year single-centre study, we investigate the community ESBL-E influx...
5.
Genomic epidemiological analysis of a single-centre polyclonal outbreak of , Belgium, 2022 to 2023
Van Goethem S, Xavier B, Glupczynski Y, Berkell M, Willems P, Van Herendael B, et al.
Euro Surveill . 2024 Nov; 29(48). PMID: 39611205
is an opportunistic pathogen with a propensity to cause nosocomial outbreaks, particularly in neonatal intensive care units (NICUs). We present a sustained outbreak spanning over 18 months (1 January 2022-29...
6.
A longitudinal point prevalence survey of antimicrobial use and resistance in tertiary care hospitals in Kerman: results from the national Iranian multicenter point prevalence survey of antimicrobials in 2021
Hosseininasab A, Barshan F, Farsiu N, Nakhaie M, Soltani J, Versporten A, et al.
BMC Infect Dis . 2024 Nov; 24(1):1300. PMID: 39543480
Background: The Global Point Prevalence Survey (PPS) of antimicrobial consumption and resistance has been widely undertaken to combat the global threat of antimicrobial resistance (AMR). This study was conducted in...
7.
Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper
Bethe U, Pana Z, Drosten C, Goossens H, Konig F, Marchant A, et al.
Infection . 2024 Jul; 52(6):2135-2144. PMID: 39017997
Background: WHO postulates the application of adaptive design features in the global clinical trial ecosystem. However, the adaptive platform trial (APT) methodology has not been widely adopted in clinical research...
8.
A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease
Arconada Nuin E, Vilken T, Xavier B, Doua J, Morrow B, Geurtsen J, et al.
J Antimicrob Chemother . 2024 Jul; 79(9):2142-2151. PMID: 39001716
Objectives: Escherichia coli can cause infections in the urinary tract and in normally sterile body sites leading to invasive E. coli disease (IED), including bacteraemia and sepsis, with older populations...
9.
Did aetiology matter in illness duration and complications in patients presenting in primary care with acute respiratory tract infections early in the COVID-19 pandemic: An observational study in nine countries
Venekamp R, Eijkemans M, Zuithoff N, Bohmer F, Chlabicz S, Colliers A, et al.
Eur J Gen Pract . 2024 Jul; 30(1):2376084. PMID: 38995056
Background: Despite considerable research into COVID-19 sequelae, little is known about differences in illness duration and complications in patients presenting in primary care with symptoms of acute respiratory tract infections...
10.
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)
Stemler J, Yeghiazaryan L, Stephan C, Mohn K, Carcas-Sansuan A, Rodriguez E, et al.
Int J Infect Dis . 2024 Jul; 146:107161. PMID: 38992789
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA...